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In the past decades, progestogens have been the
‘cornerstone’ of treatment for metastatic endometrial
cancer. The oestrogen receptor (ER) and progesterone
receptor (PR) levels are related to the stage, grade and
prognosis of the disease. The response to progestogens is
related to the PR-status (Table 1). However, progesto-
gens have no proven eﬀect in the adjuvant setting [1].
The optimal dose of progestogen has been debated.
In a Gynaecologic Oncology Group (GOG)-trial, ran-
domising 299 patients with metastatic endometrial can-
cer, it was shown that 200 mg of Medroxyprogesterone
Acetate (MPA) was as eﬀective as 1000 mg MPA daily
[10]. Based on this trial, a daily dose of 200 mg MPA is
recommended for the treatment of recurrent or meta-
static endometrial cancer.
Adjuvant tamoxifen treatment increases the risk of
endometrial carcinoma in breast cancer patients, with a
hazard ratio of 2.5 being reported [11]. Despite this, ta-
moxifen has also been shown to be active in advanced or
recurrent endometrial cancer, resulting in response rates
of 29% (Table 2). When tamoxifen is combined with
progestogens the response rates did not improve [20–22].
Raloxifene, another selective oestrogen receptor
modulator (SERM), is not associated with an increased
risk of endometrial cancer [23]. A newer SERM, ar-
zoxifene, has also been investigated by McMeekin and
colleague [24], and the response rate in 34 patients
treated with 20 mg was 31%. However, all these patients
were progestagen-sensitive. In a more recent European
study, 66 patients with recurrent or metastatic en-
dometrial cancer were treated with arzoxifene. In this
study, the overall response rate was 25% (34% in pro-
gestagen-sensitive patients). As with other SERMS, a
possible relationship between arzoxifene and an in-
creased risk of pulmonary embolisms was observed.
The newer third generation aromatase inhibitors have
also been explored as treatments for endometrial cancer.
In a GOG phase II study 1 mg of anastrozole was given
to 23 patients. Only 2 of 23 patients had a partial re-
mission (both were progestagen-sensitive) [25]. Other
third generation aromatase inhibitors, letrozole and
exemestane, are presently under investigation.
Danozole, interferes with the function of the pituitary
gonadotropins and is an inhibitor of ovarian
Table 1
Progesterone Receptor and response to progestagens in endometrial cancer
Authors (year) [Ref.] PR-negative PR-Positive
Responders Total Responders Total
Martin (1979) [2] 1 6 13 14
McCarthy (1979) [3] 0 8 4 5
Benraad (1980) [4] 2 7 5 6
Creasman (1980) [5] 1 8 3 5
Kauppila (1982) [6] 1 17 2 4
Pollow (1983) [7] 0 13 9 9
Quinn (1985) [8] 0 13 3 10
Ehrlich(1988) [9] 6 34 6 10
Total 11 (10%) 106 45 (71%) 63
PR, progesterone receptor.
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steroidogenesis, reversing endometrial hyperplasia in
97% of patients [26]. However, this drug produced no
responses in a GOG phase II study in recurrent en-
dometrial cancer patients (N=22) [27]. Disappointing
results were also obtained using Gonadotrophin-releas-
ing hormone (GnRH)-agonists [28].
Fulvestrant is a new type of ER antagonist that
downregulates cellular levels of the ER. Fulvestrant in-
hibits oestrogen-stimulated thickening of the en-
dometrium [29]. This compound merits further
investigation in the treatment of metastatic endometrial
cancer.
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